Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer

This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2, ER+/HER2− measurable or evaluable metastatic BC. Prior fulvestrant was allowed. Fulvestrant was administered at 500 mg IM on...

Descripción completa

Detalles Bibliográficos
Autores principales: Elias, Anthony D., Spoelstra, Nicole S., Staley, Alyse W., Sams, Sharon, Crump, Lyndsey S., Vidal, Gregory A., Borges, Virginia F., Kabos, Peter, Diamond, Jennifer R., Shagisultanova, Elena, Afghahi, Anosheh, Mayordomo, Jose, McSpadden, Tessa, Crawford, Gloria, D’Alessandro, Angelo, Zolman, Kathryn L., van Bokhoven, Adrie, Zhuang, Yonghua, Gallagher, Rosa I., Wulfkuhle, Julia D., Petricoin III, Emanuel F., Gao, Dexiang, Richer, Jennifer K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199936/
https://www.ncbi.nlm.nih.gov/pubmed/37210417
http://dx.doi.org/10.1038/s41523-023-00544-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199936/
https://www.ncbi.nlm.nih.gov/pubmed/37210417
http://dx.doi.org/10.1038/s41523-023-00544-z

Ejemplares similares